Iris Medicine

pioneering a new RNA modality: small binding RNAs (sbRNAs). The sbRNA platform unlocks multiple therapeutic approaches, from allele-selective inhibition to gene activation to splicing modulation. Our mission is to address a range of serious diseases, beginning with devastating repeat expansion disorders.